T0	Participants 92 99	humans.
T1	Participants 456 533	a randomized study of patients with gastric, pancreatic and colorectal cancer
T2	Participants 604 670	a randomized study of patients with resectable cancer of the colon
T3	Participants 712 784	of patients with malignant melanoma and stage IV carcinoma of the breast
T4	Participants 820 925	of patients with advanced gastrointestinal cancer selective stimulation of the immune system with NED 137